This grant has ended and is part of our past portfolio of work.
Muktar Aliyu, M.D., M.P.H., Dr.P.H.
Michael DeBaun, M.D., M.P.H.
Hydroxyurea for Stroke Prevention in Children with Sickle Cell Disease in Sub-Saharan Africa
Our goals are: 1) to assess the efficacy of moderate dose HU therapy for secondary stroke prevention when compared to low dose HU therapy among children with SCA; and 2) to determine whether moderate HU therapy decreases the rate of all-cause hospitalizations when compared to low dose HU therapy.